Glutamine antagonists may KEAP lung cancer in check.

Published in: Science advances (2024)

The glutamine antagonist DRP-104 blocks purine synthesis and combines with checkpoint inhibitors to promote antitumor immunity in KEAP1/NRF2-mutant lung cancers.

Keyphrases

protein protein
dna damage
oxidative stress
cell cycle
small molecule
young adults
cell proliferation